Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis
- PMID: 23723333
- PMCID: PMC4063392
- DOI: 10.1634/theoncologist.2012-0350
Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis
Abstract
Background: The primary aim of this retrospective study was to investigate intraindividual correlation of estrogen receptor (ER) status, progesterone receptor (PR) status, and HER2 status between primary breast cancer and metastatic breast cancer (mBC). Secondary aims included patients' characteristics, overall survival, feasibility of histopathological evaluation in the metastatic setting, and predictive factors associated with receptors status discordance.
Methods: Patients with either biopsy of metastatic relapse or surgery of metastasis were identified. Demographics, tumor characteristics, treatment characteristics, and ER, PR, and HER2 statuses were retrospectively obtained in patients' reports. Receptors statuses were assessed by immunohistochemistry with a positivity cutoff of more than 10% for ER and PR. HER2 was considered as positive if overexpression was scored at 3+ in immunohistochemistry or if amplification ratio was >2 in fluorescent in situ hybridization.
Results: From a cohort of 489 patients with mBC, 269 patients had histopathological samples of metastatic relapse. Histopathological analysis of the specimen confirmed the diagnosis of mBC in 235 patients. Discordance in one or more receptors between primary breast cancer and mBC was found in 99 patients (42%). A switch in receptor status was identified for ER in 17% of tumors (p = 4 × 10(-3)), PR in 29% of cancers (p < 4 × 10(-4)), and HER2 in 4% of lesions (p = .16). Exposure to chemotherapy and to anthracycline-based chemotherapy was statistically associated with switches in ER status. Seven (2%) second malignancies and three benign diseases (1%) were diagnosed.
Conclusions: This study confirms that discordance in ER and PR receptor expression between the primary breast tumor and the corresponding metastatic lesions is high, whereas HER2 status remains relatively constant. Chemotherapy, and specifically anthracycline-based chemotherapy, was associated with switch in ER status. These results were obtained in a selected population of patients; further studies are warranted to confirm these data and to determine the interest of systematic rebiopsy in the metastatic setting.
Keywords: Breast cancer; Estrogen receptor; Human epidermal growth factor receptor 2; Progesterone receptor.
Conflict of interest statement
Disclosures of potential conflicts of interest may be found at the end of this article.
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4063392/bin/onc0051313070001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4063392/bin/onc0051313070002.gif)
![Figure 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4063392/bin/onc0051313070003.gif)
![Figure 4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4063392/bin/onc0051313070004.gif)
Similar articles
-
Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.Oncologist. 2015 May;20(5):466-73. doi: 10.1634/theoncologist.2014-0107. Epub 2015 Mar 23. Oncologist. 2015. PMID: 25802405 Free PMC article.
-
Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.Indian J Cancer. 2020 Apr-Jun;57(2):190-197. doi: 10.4103/ijc.IJC_610_18. Indian J Cancer. 2020. PMID: 32445323
-
Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.Breast Cancer Res Treat. 2020 Aug;183(1):137-144. doi: 10.1007/s10549-020-05746-8. Epub 2020 Jul 1. Breast Cancer Res Treat. 2020. PMID: 32613540 Free PMC article.
-
Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.Cancer Metastasis Rev. 2016 Sep;35(3):427-37. doi: 10.1007/s10555-016-9631-3. Cancer Metastasis Rev. 2016. PMID: 27405651 Review.
-
Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis.Breast Cancer Res Treat. 2022 Jan;191(1):1-14. doi: 10.1007/s10549-021-06390-6. Epub 2021 Oct 6. Breast Cancer Res Treat. 2022. PMID: 34613502 Free PMC article. Review.
Cited by
-
Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival.Breast Cancer Res Treat. 2024 May 23. doi: 10.1007/s10549-024-07368-w. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 38780889
-
Clinicopathologic features and genomic profiling of female axillary lymph node metastases from adenocarcinoma or poorly differentiated carcinoma of unknown primary.J Cancer Res Clin Oncol. 2024 May 15;150(5):256. doi: 10.1007/s00432-024-05783-6. J Cancer Res Clin Oncol. 2024. PMID: 38750402 Free PMC article.
-
Hormone receptor conversion in metastatic breast cancer.Rep Pract Oncol Radiother. 2024 Feb 16;28(6):746-755. doi: 10.5603/rpor.98730. eCollection 2023. Rep Pract Oncol Radiother. 2024. PMID: 38515821 Free PMC article.
-
Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial.Breast Cancer Res Treat. 2024 May;205(1):87-95. doi: 10.1007/s10549-023-07231-4. Epub 2024 Jan 31. Breast Cancer Res Treat. 2024. PMID: 38291268 Free PMC article. Clinical Trial.
-
Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer.Breast Cancer Res. 2023 Nov 15;25(1):145. doi: 10.1186/s13058-023-01743-z. Breast Cancer Res. 2023. PMID: 37968696 Free PMC article.
References
-
- Cardoso F, Costa A, Norton L, et al. First international consensus guidelines for advanced breast cancer (ABC 1) Breast. 2012;21:242–252. - PubMed
-
- Amir E, Clemons M. Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? Lancet Oncol. 2009;10:933–935. - PubMed
-
- Brennan MJ, Donegan WL, Appleby DE. The variability of estrogen receptors in metastatic breast cancer. Am J Surg. 1979;137:260–262. - PubMed
-
- Brunn Rasmussen B, Kamby C. Immunohistochemical detection of estrogen receptors in paraffin sections from primary and metastatic breast cancer. Pathol Res Pract. 1989;185:856–859. - PubMed
-
- Wilking U, Karlsson E, Skoog L, et al. HER2 status in a population-derived breast cancer cohort: Discordances during tumor progression. Breast Cancer Res Treat. 2011;125:553–561. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous